Merit Medical Systems (NASDAQ:MMSI) Price Target Raised to $105.00 at BTIG Research

Merit Medical Systems (NASDAQ:MMSI) had its price objective hoisted by equities researchers at BTIG Research from $100.00 to $105.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research’s price objective indicates a potential upside of 25.97% from the stock’s previous close.

Several other research analysts have also weighed in on MMSI. Compass Point set a $107.00 price objective on shares of Merit Medical Systems in a report on Monday, April 20th. Citigroup restated an “outperform” rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Needham & Company LLC raised their price target on shares of Merit Medical Systems from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday. Piper Sandler reissued an “overweight” rating on shares of Merit Medical Systems in a report on Friday, July 10th. Finally, Weiss Ratings downgraded Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Merit Medical Systems currently has a consensus rating of “Moderate Buy” and an average price target of $92.78.

Merit Medical Systems Stock Up 3.1%

NASDAQ MMSI opened at $83.35 on Friday. The stock has a market cap of $4.97 billion, a PE ratio of 36.08, a P/E/G ratio of 2.51 and a beta of 0.52. The business has a 50 day moving average price of $69.45 and a two-hundred day moving average price of $71.69. Merit Medical Systems has a fifty-two week low of $59.74 and a fifty-two week high of $94.75. The company has a quick ratio of 3.46, a current ratio of 5.08 and a debt-to-equity ratio of 0.45.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The business had revenue of $418.84 million during the quarter, compared to analyst estimates of $405.25 million. During the same period last year, the business earned $1.01 EPS. The business’s revenue was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, sell-side analysts predict that Merit Medical Systems will post 3.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Lynne N. Ward sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $62.61, for a total transaction of $313,050.00. Following the transaction, the director owned 7,809 shares in the company, valued at $488,921.49. This trade represents a 39.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian G. Lloyd purchased 2,000 shares of the stock in a transaction dated Thursday, May 7th. The shares were purchased at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the transaction, the insider owned 2,000 shares in the company, valued at $125,240. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp increased its stake in Merit Medical Systems by 1.5% in the 4th quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock worth $196,645,000 after purchasing an additional 32,459 shares in the last quarter. Conestoga Capital Advisors LLC lifted its stake in Merit Medical Systems by 3.9% during the first quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock valued at $149,407,000 after buying an additional 81,030 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its stake in Merit Medical Systems by 12.7% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock valued at $183,137,000 after buying an additional 234,682 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Merit Medical Systems by 7.0% in the fourth quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock worth $116,963,000 after buying an additional 86,504 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Merit Medical Systems by 1.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier’s stock worth $85,287,000 after buying an additional 12,285 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Strong earnings and revenue beat: Second-quarter revenue rose 9.5% year over year to $418.8 million, surpassing the $405.3 million consensus estimate. Non-GAAP EPS increased 18% to $1.19, well above expectations of $0.96 and the year-ago result of $1.01. GAAP operating margin also improved to 14.4% from 12.3%. Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance
• Positive Sentiment: Raised full-year guidance: Merit now expects fiscal 2026 adjusted EPS of $4.25 to $4.35, above the prior consensus estimate of $3.98. Revenue guidance remains approximately $1.6 billion, broadly in line with expectations, suggesting the primary upside is coming from earnings and margin performance. Merit Medical Raises 2026 Outlook on Strong Q2 Results
• Positive Sentiment: Analyst confidence increased: Following the earnings beat and guidance increase, multiple analysts maintained Buy ratings and raised their price targets, reinforcing expectations for continued earnings growth. Analysts Increase Forecasts on Merit Medical Systems After Strong Q2 Results
• Negative Sentiment: Cash generation softened: Year-to-date operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million. Investors may monitor whether this reflects temporary working-capital needs or a sustained pressure on cash conversion. Merit Medical Second-Quarter Results

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.